Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884654 | 0.86 | MC4R (0.48) | MEN1KMT2A | |
| SCHEMBL901839 | 0.83 | REN (0.50) | MEN1KMT2ASMN1; SMN2ALDH1A1REN | |
| SCHEMBL23754645 | 0.79 | ALDH1A1 (0.45) | MEN1KMT2ASMN1; SMN2ALDH1A1REN | |
| SCHEMBL4202967 | 0.78 | MAOB (0.57) | ACHEALDH1A1BCHE | |
| SCHEMBL3897221 | 0.78 | LMNA (0.52) | MEN1KMT2ASMN1; SMN2ALDH1A1REN | |
| SCHEMBL2582068 | 0.78 | ALDH1A1 (0.44) | MEN1KMT2ASMN1; SMN2ALDH1A1REN | |
| SCHEMBL9257077 | 0.76 | TDP1 (0.53) | MEN1KMT2A | |
| SCHEMBL9262777 | 0.76 | IDO1 (0.52) | MEN1KMT2A | |
| SCHEMBL7621746 | 0.76 | TDP1 (0.53) | MEN1KMT2A | |
| SCHEMBL454150 | 0.76 | TDP1 (0.53) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013183-B1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2011-11-02 | — | — | EP | disclosed |
| US-20090082378-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-03-26 | — | — | US | disclosed |
| EP-2013183-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR | Laboratorios Almirall, S.A. (ES) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007124898-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | LABORATORIOS, ALMIRALL S.A. (ES) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082378-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXIETHYL)PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | ADRB2, ADRA2C, ADRB1 | MEN1 4112/4885KMT2A 2632/4885ACHE 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.